Levosimendan in LCOS $600 million U.S. market.
FACTS
- Ladenburg Thalmann believes that Levosimendan has a market potential of $600 million in the US market just for LCOS.
- Institutional investors are holding over 50% of the shares of Tenax Therapeutics. They are in for the long term as the potential of this product, its indications and the strategy presented, convinced them to invest.
- This company has changed for the good and trials are moving with sufficient funds in place to finish phase 3.
- In addition, the FDA granted fast track status, which potentially indicates (if data is as expected) that this product could be generating revenues faster then the market is currently expecting.
Opinion
This stock is massively undervalued compared to other companies with phase 3 and phase 2 trials ongoing. The current stock price might be justified if only looking at the track record of this company , past management skills and strength of short acting companies. But the upside today is much greater than the downside (well, hopefully, and actually not that difficult, as the stock is down over 95% since 2008) and absolutely worth the gamble at this stage. The potential of this stock being much higher in 12 month is not only possible but is most likely - obviously conditional to the data of the trials (this product is approved in over 50 countries already and if management is not able to have set up a protocol which will clearly pass the FDA, then this stock does not deserve to be traded at all.
The current market capitalisation of just about $80 million reflects the market opinion, which translates in,
-no trust, no capability, no market potential, no chance of good data, no management skills to potentially monetize on the opportunity, no nothing...I personally disagree with most of those assumptions.... GLTA
